A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Disease (PADN-HF-PH)

Inclusion Criteria: Age ≥18, ≤75 years old; Diagnosed with chronic heart failure for at least 3 months, and have received the GDMT pharmacological treatment based on the 2022 AHA/ACC Guidelines for Heart Failure for at least 1 month; Clinically stable defined by No intravenous diuretics, inotropes or vasodilators for at least 1 month, and Systolic blood pressure (SBP) ≥ 100 and < 160 mmHg and resting heart rate (HR) ≥50 and <100 bpm (<110 bpm for atrial fibrillation) on the day of the procedure ACC/AHA stage of heart failure B-C; New York Heart Association (NYHA) class II-IVa; World Health Organization (WHO) functional class II-IV; 6MWD ≥ 100 m and < 450 m; NT-proBNP > 600 pg/mL (BNP > 150 pg/mL), or NT-proBNP > 400 pg/mL (BNP >100pg/mL) and has been hospitalized for heart failure in the past 1 year; Hemodynamic indicators (RHC) : Mean pulmonary arterial pressure (mPAP) > 25mmHg Pulmonary capillary wedge pressure (PCWP) >15mmHg Understand and be willing to sign informed consent, and be willing to follow the follow-up plan required by the protocol. Exclusion Criteria: Any of the following: Hypertrophic cardiomyopathy with left ventricular (LV) outflow tract obstruction or systolic anterior motion (SAM); pericardial disease; infiltrative or inflammatory myocardial disease; valvular heart disease with moderate or severe stenosis of any of the 4 valves, or severe regurgitation of any of the 4 valves, or active endocarditis; or Symptomatic carotid stenosis, or transient ischemic attack (TIA) or stroke within 30 days prior to randomization; or Complex congenital heart disease; or Have received any revascularization, including coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) within 6 months prior to randomization; or anticipated to undergo coronary revascularization (CABG or PCI) within 6 months; or Artificial pacemakers, including single-chamber, dual-chamber and three-chamber pacemakers, have been implanted or are anticipated to be implanted within 6 months; or Anticipated to undergo ablation of atrial fibrillation within 6 months; or Anticipated to undergo heart valve surgery (valve replacement, valvuloplasty) within 6 months; or Listing for heart/heart-lung transplantation or anticipated to implant a ventricular assist device (VAD) Other types of pulmonary hypertension, including WHO Group1, Group3, Group4, Group5; Received pulmonary arterial hypertension (PAH) targeted drugs within 1 month prior to randomization; Anticipated to undergo any surgery within 6 months; The cardiac index (CI) of RHC < 1.5L/min/m²; Severe renal insufficiency (eGFR <30mL/min/1.73m² by MDRD formula); Severe liver insufficiency (Child-Pugh classification B-C); Platelet count < 50 × 10^9/L; Life expectancy <1 year; Systemic inflammation or other disease requiring long-term use of glucocorticoids or immunosuppressants; Active infection requiring oral or intravenous antibiotics; Cannot tolerate any GDMT medicine; Body mass index (BMI) >40 kg/m²; Pregnant or lactating women, or plan to pregnant in one year; Participated in other clinical trials within 3 months prior to signing the informed consent; Any other circumstances that investigators deem inappropriate to participate in this trial.